Your browser doesn't support javascript.
loading
Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Years.
Gandhi, Sacha E; Zerenner, Tanja; Nodehi, Anahita; Lawton, Michael A; Marshall, Vicky; Al-Hajraf, Falah; Grosset, Katherine A; Morris, Huw R; Hu, Michele T; Ben-Shlomo, Yoav; Grosset, Donald G.
Afiliación
  • Gandhi SE; School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
  • Zerenner T; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Nodehi A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Lawton MA; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Marshall V; Institute of Neurological Sciences, Glasgow, United Kingdom.
  • Al-Hajraf F; Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neuroscience, Oxford University, Oxford, United Kingdom.
  • Grosset KA; Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
  • Morris HR; School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
  • Hu MT; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
  • Ben-Shlomo Y; Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neuroscience, Oxford University, Oxford, United Kingdom.
  • Grosset DG; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Mov Disord Clin Pract ; 11(6): 686-697, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38587023
ABSTRACT

BACKGROUND:

Motor complications are well recognized in Parkinson's disease (PD), but their reported prevalence varies and functional impact has not been well studied.

OBJECTIVES:

To quantify the presence, severity, impact and associated factors for motor complications in PD.

METHODS:

Analysis of three large prospective cohort studies of recent-onset PD patients followed for up to 12 years. The MDS-UPDRS part 4 assessed motor complications and multivariable logistic regression tested for associations. Genetic risk score (GRS) for Parkinson's was calculated from 79 single nucleotide polymorphisms.

RESULTS:

3343 cases were included (64.7% male). Off periods affected 35.0% (95% CI 33.0, 37.0) at 4-6 years and 59.0% (55.6, 62.3) at 8-10 years. Dyskinesia affected 18.5% (95% CI 16.9, 20.2) at 4-6 years and 42.1% (38.7, 45.5) at 8-10 years. Dystonia affected 13.4% (12.1, 14.9) at 4-6 years and 22.8% (20.1, 25.9) at 8-10 years. Off periods consistently caused greater functional impact than dyskinesia. Motor complications were more common among those with higher drug doses, younger age at diagnosis, female gender, and greater dopaminergic responsiveness (in challenge tests), with associations emerging 2-4 years post-diagnosis. Higher Parkinson's GRS was associated with early dyskinesia (0.026 ≤ P ≤ 0.050 from 2 to 6 years).

CONCLUSIONS:

Off periods are more common and cause greater functional impairment than dyskinesia. We confirm previously reported associations between motor complications with several demographic and medication factors. Greater dopaminergic responsiveness and a higher genetic risk score are two novel and significant independent risk factors for the development of motor complications.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Clin Pract Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Clin Pract Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido